Clinical Trials Logo

Stomach Neoplasms clinical trials

View clinical trials related to Stomach Neoplasms.

Filter by:

NCT ID: NCT05536102 Recruiting - Gastric Cancer Clinical Trials

The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)

Start date: September 5, 2022
Phase: Phase 2
Study type: Interventional

This is a signle-arm, multi-center, open-lable, phase II study. The objective is to evaluate the effectiveness and safety of tislelizumab + oxaliplatin + capecitabine + PLD in the neoadjuvant treatment of resectable gastric adenocarcinoma.

NCT ID: NCT05535569 Completed - Clinical trials for Recurrent/Metastatic Gastric Cancer

Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer

Start date: July 17, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase Ib/II study to identify the recommended dose of paclitaxel and nivolumab for further study, and to assess the safety and clinical efficacy of this combined treatment in EBV-related, MSI-high, or PD-L1 positive advanced gastric cancer after first line treatment.

NCT ID: NCT05529667 Completed - Clinical trials for Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel

Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.

Start date: May 27, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This study was conducted as a second-line treatment of recurrent / progressive gastric cancer patients with FGFs / FGFRs genetic mutations in the Ib / II clinical trial. The maximum maximal tolerated dose (MTD) and 2-phase recommended dose in combination with INCB054828 and paclitaxel (recommended phase II dose, RP2D), and evaluate the safety and clinical efficacy of this combination therapy. This study consists of two steps: Phase 1 is a dose escalation study to determine the maximum tolerated dose and 2-phase recommended dose of weekly paclitaxel and INCB054828 combination therapy, and Phase 2 is the dose escalation study in combination with INCB054828 and paclitaxel Assess safety and tolerability and identify antitumor effects in stomach cancer with FGFs / FGFRs genetic mutations.

NCT ID: NCT05528367 Recruiting - Clinical trials for Locally Advanced Gastric Cancer

Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Start date: January 1, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of chemoradiotherapy combined with tirelizumab in the treatment of initial unresectable locally advanced gastric cancer or gastroesophageal junction cancer.

NCT ID: NCT05524974 Not yet recruiting - Clinical trials for Locally Advanced Gastric Cancer

Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

Start date: September 1, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the clinical efficacy of camrelizumab, apatinib Mesylate and nab-paclitaxel combined with oxplatin and S-1 in the neoadjuvant treatment of locally advanced gastric cancer with different genotypes

NCT ID: NCT05519202 Not yet recruiting - Gastric Cancer Clinical Trials

Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer

Start date: August 31, 2022
Phase: Phase 2
Study type: Interventional

To explore the efficacy and safety of Penpulimab combined with SOX in the perioperative treatment of gastric cancer

NCT ID: NCT05515796 Recruiting - Gastric Cancer Clinical Trials

Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

Start date: September 1, 2022
Phase: Phase 2
Study type: Interventional

immunotherapy,gastric cancer,rectal cancer,biomark

NCT ID: NCT05514769 Recruiting - Gastric Cancer Clinical Trials

Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty Versus Esophagogastric Anastomosis for Gastric Cancer

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

This research is designed to compare proximal gastrectomy anterior anastomosis with pyloroplasty with esophagogastric anastomosis for gastric cancer. Gastroesophageal reflux disease, postoperative quality of life, short term outcomes, and long term outcomes will be compared.

NCT ID: NCT05514158 Recruiting - Gastric Cancer Clinical Trials

To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)

Start date: September 28, 2022
Phase: Phase 1
Study type: Interventional

This is a single-center, open-label, dose-escalation phase I clinical study.This study aimed to evaluate the safety, tolerability, pharmacokinetics and preliminary clinical efficacy of RC48-ADC combined with RC98 in subjects with advanced gastric cancer.Which will provide a reference basis for dose confirmation in subsequent clinical studies.

NCT ID: NCT05513144 Recruiting - Gastric Cancer Clinical Trials

Potential Clinical Utilities of Circulating Tumor DNA in Advanced HER2 Negative Gastric Cancer

Start date: December 24, 2021
Phase:
Study type: Observational

This study aims to evaluate the use of next generation sequencing (NGS) to detect circulating tumor DNA in advanced HER2 negative gastric cancer patients. The evaluation of the therapy efficacy for gastric cancer patients is usually evaluated by computer tomography scans with RECIST criteria that are performed every two months during the treatment. In this study, we will compare the monitoring of circulating tumor DNA with the results of CT scan according the RECIST criteria and the blood level of CEA and CA 19-9 tumor markers.